These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15152631)

  • 1. Monoclonal antibodies market.
    Reichert J; Pavolu A
    Nat Rev Drug Discov; 2004 May; 3(5):383-4. PubMed ID: 15152631
    [No Abstract]   [Full Text] [Related]  

  • 2. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 3. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 4. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 6. Fresh from the biologic pipeline-2009.
    Sheridan C
    Nat Biotechnol; 2010 Apr; 28(4):307-10. PubMed ID: 20379168
    [No Abstract]   [Full Text] [Related]  

  • 7. PDL's mAb technology finds right timing.
    Fletcher L
    Nat Biotechnol; 2001 May; 19(5):395-6. PubMed ID: 11328982
    [No Abstract]   [Full Text] [Related]  

  • 8. The therapeutic antibodies market to 2008.
    Pavlou AK; Belsey MJ
    Eur J Pharm Biopharm; 2005 Apr; 59(3):389-96. PubMed ID: 15760719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotech hits regulatory doldrums.
    Lawrence S
    Nat Biotechnol; 2005 Jun; 23(6):644. PubMed ID: 15940226
    [No Abstract]   [Full Text] [Related]  

  • 10. Similarity trials.
    Nat Biotechnol; 2011 Jan; 29(1):1. PubMed ID: 21221076
    [No Abstract]   [Full Text] [Related]  

  • 11. [Xolair is approved in the USA and the EU].
    Kärnell A
    Lakartidningen; 2006 May 3-9; 103(18):1450; author reply 1450-1. PubMed ID: 16729460
    [No Abstract]   [Full Text] [Related]  

  • 12. Difficult decisions.
    Nat Med; 2011 Aug; 17(8):901. PubMed ID: 21818065
    [No Abstract]   [Full Text] [Related]  

  • 13. The origins of new drugs.
    Kneller R
    Nat Biotechnol; 2005 May; 23(5):529-30. PubMed ID: 15877061
    [No Abstract]   [Full Text] [Related]  

  • 14. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 15. Genentech and IDEC await approval of lymphoma Mab.
    Nat Biotechnol; 1997 Apr; 15(4):301. PubMed ID: 9094110
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoclonal antibody successes in the clinic.
    Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
    Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genentech relaunched with independence intact.
    Glaser V
    Nat Biotechnol; 1999 Jul; 17(7):634. PubMed ID: 10409348
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechnology drugs create new maze of concerns for hospitals.
    Lumsdon K
    Hospitals; 1991 Dec; 65(23):32, 34-5. PubMed ID: 1937456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Just mad about mAbs.
    Jacobs T
    Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
    [No Abstract]   [Full Text] [Related]  

  • 20. Pipelines turn to biotech.
    Lawrence S
    Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.